The 3' end of the turkey coronavirus (TCV) genome and the gene encoding the nucleocapsid protein (N) were cloned and sequenced. The gene encoding the membrane protein (M) was obtained by cloning a polymerase chain reaction (PCR)-amplified fragment obtained using bovine coronavirus (BCV)-specific primers. Furthermore, five TCV DNA fragments, obtained by PCR on RNA from clinical specimens and corresponding to either the N terminus of the M protein or the complete M protein were also cloned and sequenced. The sequence revealed a 3' non-coding region of 291 bases, an open reading frame (ORF) encoding the N protein with a predicted size of 448 amino acids, or an Mr of 49K, and an ORF encoding the M protein with a predicted size of 230 amino acids and an Mr of 26K. A third ORF, encoding a hypothetical protein of 207 amino acids with an Mr of 23K was found within the N gene sequence. The amino acid sequences of both the N and M proteins were more than 99% similar to those published for BCV. Extensive similarity was also observed between the amino acid sequences of the TCV N protein and those of murine hepatitis virus (MHV) (70%) and human respiratory coronavirus strain OC43 (HCV-OC43) (98%) and between the amino acid sequences of the predicted M proteins of TCV and MHV (86 %). Such striking identity suggests that BCV, TCV and HCV-OC43 must have diverged from each other only recently. A potential N-glycosylation site was found at the N terminus of the TCV M protein and is situated at the same location in BCV, MHV and transmissible gastroenteritis virus. 0001-0062 © 1991 SGM
Introduction
The Coronaviridae family contains four antigenic groups (Pederson et al., 1978; Sturman & Holmes, 1983) . Viruses within each group possess partial antigenic cross-reactivities and infect a variety of mammalian and avian species . The viruses possess a single-stranded, polyadenylated RNA genome of about 20 to 30 kb. The genes encoding the viral structural proteins are situated on the last quarter of the 3' end of the genome. Except for the nucleocapsid protein (N), all other structural proteins so far identified are associated with the lipid membrane. The integral membrane protein (M), which is largely embedded in the lipid bilayer targets the site of virus morphogenesis (Tooze et al., 1984) and may be implicated in viral pathogenesis (Fleming et al., 1989) , whereas the bulbous peplomer (S) protein is responsible for virus binding (Cavanagh & Davis, 1986; Koch et al., 1990) as well as virulence and tissue tropism (Wege et al., 1988 ). An additional surface protein (HE), responsible for haemagglutination, has been found in bovine coronavirus (BCV; King et al., 1985; Hogue et al., 1989; Parker et al., 1989) , human respiratory coronavirus strain OC43 (HCV-OC43; Hogue & Brian, 1985) , haemagglutinating encephalitis virus of swine (Callebaut & Pensaert, 1980) , diarrhoea virus of infant mice (Sugiyama et al., 1986) and turkey coronavirus (TCV; Dea et al., 1986) . The HE protein of BCV also exhibits an acetyl esterase receptor-destroying activity similar to the activity found in influenza C viruses (Vlasak et al., 1988) .
Our recent studies demonstrated a close antigenic relatedness between TCV and BCV; only a few monoclonal antibodies produced against either of the two viruses were able to differentiate between them, indicating that TCV, which is still placed in an antigenic group distinct from avian infectious bronchitis virus (IBV) and the mammalian coronaviruses, should be reclassified . Homology between BCV and TCV was further established in hybridization assays (unpublished results) . It was demonstrated that BCVspecific probes were efficient in detection and clinical diagnosis of TCV. In order to determine the extent of homology between the two viruses, we cloned and sequenced the genes encoding the N and M proteins. One of the structural differences observed between TCV and BCV is the type of glycosylation of the M protein, which is N-and O-glycosylated in TCV and BCV, respectively (Dea et al., 1989a; Lapps et al., 1987) . We therefore used the polymerase chain reaction (PCR) on nucleic acid isolated from TCV-positive clinical specimens to obtain the M gene or gene fragments corresponding to the N-terminal portion of the M protein. These fragments were cloned and sequenced to establish possible sequence differences associated with the predicted glycosylation sites and to confirm the reliability of the obtained TCV sequence.
Methods
Virus and cells. The prototype Minnesota strain of TCV (TCV-Minnesota) (Ritchie et al., 1973) , kindly supplied by Dr B. S. Pomeroy (College of Veterinary Medicine, St Paul, Mn., U.S.A.), was initially serially propagated by inoculation into the amniotic cavity of 22-to 24day-old embryonating turkey eggs and further propagated on H RT-I 8 cells in the presence of I unit/ml bovine pancreatic trypsin as described earlier (Laporte et aL, 1980; Dea et al., 1989b) .
Synthesis and cloning of eDNA. Purified, tissue culture-adapted TCV-Minnesota was used for the extraction of RNA (Verbeek & Tijssen, 1988) , which was reverse transcribed according to standard procedures (Binns et al., 1985; Gubler & Hoffman, 1983) . Tailing (Roychoudhury & Wu, 1980) and cloning of eDNA molecules for the construction of a genomic library was as described for BCV (Verbeek & Tijssen, 1988) .
Clone selection and DNA sequencing. Clones from the TCV eDNA library were screened in duplicate by colony hybridization assays (Grunstein & Hogness, 1975) with one probe (a 32p-labelled recombinant plasmid; Rigby et al., 1977) containing sequences corresponding to the 3' end of the BCV genome as well as a part of the N gene, and another probe containing the additional upstream sequences of the BCV N gene . This approach was chosen because 32p-labelled BCV-specific recombinant plasmids were capable of detecting many TCV isolates and TCV present in clinical samples (unpublished results) . Clones that hybridized with both probes were selected for further characterization. Two PstI-generated insert fragments of recombinant plasmid pM78 were subcloned into replicative form DNA of bacteriophage M 13mp 19, while phage clones with opposite insert orientations, determined according to Poncz et al. (1982) , were subjected to exonuclease III/nuclease S1 degradation (Henikoff, 1984) to create clones with a nested set of deletions. The TCV M gene was obtained by cloning a fragment amplified by PCR using BCV-specific primers [PXBAV (5' GAA CAT TTC TAG ATT GGT CGG ACT G 3') reverse complementary to the sequence located 1527 to 1551 nucleotides from the 3' end and PC (5" ATG AGT AGT GTA ACT ACA CCA GCA Y) hybridizing to nucleotides 2314 to 2337 from the 3' end] and TCV-Minnesota genomic RNA. The insert from recombinant plasmid pME1 was subcloned in M13mpl9 and sequenced in both directions as described above for pM78. Sequencing was according to the method of Sanger et al. (1977) . Sequences were analysed and compared with the IBI Pustell sequence programs.
Amplification by PCR using RNA isolated from TCV-positive clinical specimens. The supernatant (100 ~tl) of clarified intestinal contents was supplemented with 1 ~tg of tRNA (Sigma) before RNA extraction (Chomczynski & Sacchi, 1987) . RNA was reverse-transcribed as corresponding to the N and M genes, respectively, pQE7 contains a PCR-amplified fragment, corresponding to the M gene of TCV Quebec isolate number 6. All inserts were also subcloned in M13 mpl9, analysed for their orientation and subjected to unidirectional deletion. The arrows represent sequences obtained from the deleted-insert clones.
described earlier ) using a primer complementary to BCV RNA. PCR was performed on cDNA templates with BCV sequence-specific primer combinations: (i) PIORF1 (5' GGGGGATCC TTA CAC CAG AGG TAG GGG TTC Y, reverse complementary to the sequence located 951 to 971 nucleotides from the 3' end) and PIORF2 (5' GGAAGCTT ATG (;CA TCC TTA AGT GGG CCG, complementary to the sequence 1554 to 1574 nucleotides from the 3' end) to amplify the N-internal open reading frame (ORF) of 624 bp (including the translation stop codon; detecting a fragment of 640 bp containing the primer sequences), (ii) PEIE (5' GGAAGCTT ATG AGT AGT GTA ACT ACA CCA 3', complementary to the sequence 2317 to 2337 nucleotides from the 3' end) and PElF (5' GGGGATCC TTA GAT ATT ATT TCT CAA CAA T Y, reverse complementary to the sequence located 1645 to 1666 nucleotides from the 3' end) to amplify the 693 bp (including the translation stop codon) TCV M gene (709 bp, including the primer sequences) and (iii) PE1E and PE1G (5' GGGAGCTC TAA GAT GAT AGT AAG GGG CCA Y, reverse complementary to the sequence located 2131 to 2151 nucleotides from the 3" end) to amplify 207 bp fragments (223 bp, including the primer sequences) encoding the N terminus of the TCV M protein. Underlined primer sequences represent non-viral sequences containing restriction endonuclease sites. PCR was for 30 cycles under conditions described earlier and in the presence of 0-5 ~tl of [g.32 P]dCTP (ICN ; 3000 Ci/mmol, 3-3 IxM) as a tracer for the amplified fragments. *  120  ATG AGT AGT GTA ACT ACA CCA GCA CCA GTT TAC ACC TGG ACT GCT GAT GAA GCT ATT AAA TTC CTA AAG GAA TGG AAC TTT TCT TTG GGT ATT ATA CTA CTT TTT ATT ACA ATC ATA TTG  N  S  S  V  T  T TIT GGA TAT ACA AGT CGC AGT ATG TCT GTT TAT GTT ATT AAG ATG AIC AIT TTG TGG CTI ATG T G CCC CTT ACT ATC ATC TTA ACT ATT TIC /tAT TGC gTG TAT GCG ITG AAT TAT CTT GGC TTT TCT ATA GTT TTC ACT ATA GTG GCC ATT ATC ATG TGG ATT GTG TAT TTT GTG AAT AGT ATC AGG TTG TTI ATT AGA ACT GGA AGT TGG TGG AGT TTC AAC and both strands were sequenced (Fig. 1) . Sequences corresponding to the ORF of the M protein were obtained by cloning a fragment amplified by PCR using BCV-specific primers (PXBAV and PC) and RNA isolated from purified TCV-Minnesota. Clone pME1 was found to contain the expected insert of 811 bp and was subcloned for sequencing ( Fig. 1) .
Results
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Sequence analysis of TCV-Minnesota cDNA clones
The nucleotide sequence of the 3' end of the TCV genome, i.e. the N and M genes, and their predicted amino acid sequence are shown in Fig. 2. A non- consensus region, GGGAAGAGCC, at 70 to 79 bases from the 3' end. The location and sequence of this region is similar to the consensus regions found in murine hepatitis virus (MHV) and IBV (Boursnell et al., 1985) as well as the consensus published for porcine transmissible gastroenteritis coronavirus (TGEV) (Kapke & Brian, 1986) and two different strains of BCV (Lapps et al., 1987; Cruci6re & Laporte, 1988) .
The largest translational reading frame of 1344 nucleotides (292 to 1635 nucleotides from the 3' end; Fig.  2 and 3) predicted a 448 amino acid protein with an Mr of 49K, which is likely to encode the N protein because of its location and its predicted Mr which approaches that found for the TCV N protein (Dea & Tijssen, 1988) . The consensus region, AUAU-C U A A A C U U U A A G G , intergenic to N and M, was the same as that for BCV and resembled closely those observed for MHV strains A59 (Armstrong et al., 1983) and JHM (Skinner & Siddell, 1983) , and HCV-OC43 .
The second largest translational reading frame (bases 1648 to 2337 from the 3' end; Fig. 2 and 3) was predicted to encode a protein of 230 amino acids with an Mr of about 26K, which is likely to be the M protein. The predicted protein has 113 hydrophobic residues (approximately 49% hydrophobicity) with a distribution similar to the BCV and MHV hydrophobic amino acids. The first 28 N-terminal amino acid residues contain six potential sites for O-and one site for N-glycosylation. Most basic amino acid residues (17/23) were found in the C-terminal half of the protein.
An overlapping ORF (bases 951 to 1574 from the 3' end), predicting a protein of 207 amino acids with an Mr of 23K was found inside the coding sequence of the N protein ( Fig. 2 and 3) . 
Amplification by PCR
The complete M gene, or gene fragments corresponding to the N terminus of the M protein, were amplified, cloned and sequenced using eight TCV-positive clinical specimens as starting material. Similarly, TCV-cont~fining culture fluid supernatants, obtained after three passages of virus from two different clinical samples, were also subjected to PCR. Agarose gel electrophoresis of 10% of each PCR reaction mixture showed that amplification occurred in two of eight clinical specimens ( Fig. 4a, b ; lanes 5 and 6) and in both cultured isolates ( Fig. 4a, b; lanes 9 and 10) . Autoradiography revealed significant background amplification in some of the samples (Fig. 4b; lanes 1, 2 and 7) , which is not observed in samples where actual amplification has occurred. Amplified products were absent in samples after PCR using nucleic acid isolated from mock-infected HRT-18 cells (Fig. 4a, lane 11) . RNA from clinical samples 5 and 6 was also used for amplification with a combination of primers that would amplify the 624 bp internal ORF (IORF) (640 bp, including the primers) located inside the N gene, and the 693 bp ORF of the M protein (709 bp including the primers). Agarose gel electrophoresis (Fig.  4c ) of 10% of the reaction products revealed that amplification could only be detected after autoradiography of the gel in two out of four reactions (Fig. 4d) . The 709 bp amplified fragment of sample 6 ( Fig. 4c, d ; lane 4) and the 223 bp fragments of clinical samples 5, 6, 9 and 10 ( Fig. 4a, b) , were re-amplified and cloned in pUC-9 after poly(C) tailing. Mebus strain is presented schematically in Fig. 5 . The single nucleotide difference at position 149, in the M genes of TCV and BCV (Fig. 2) , was also found in the sequence of the 223 bp fragment obtained from clinical specimen 5. The sequences of the other 223 bp fragments (clinical sample 6 and those obtained from the cultured TCV isolates), as well as the complete M gene (709 bp fragment; plasmid pQE7) of TCV from clinical sample 6, were identical to the sequence published for BCV (Fig.  1, 2 and 5 ).
Sequence analysis of cloned PCR-amplified fragments
Discussion
The sequence of the first 2337 nucleotides from the 3' end of the TCV RNA genome revealed a 291 base noncoding region and two ORFs with positions corresponding to those for the N and M proteins of coronaviruses . The 3' non-coding 291 base region has a 10 nucleotide sequence (GGGAAGAGCC) which is relatively conserved throughout the Coronaviridae family and may be involved in attachment of the polymerase to initiate negative-strand RNA synthesis .
The largest translational reading frame of 1344 nucleotides was predicted to encode a 448 amino acid, 49K protein which is likely to be the N protein. The predicted protein is basic and serine-rich (43/448 amino acids) and its serine residues tend to be clustered in two regions. One of these clusters is located at the N terminus of the protein, and the other cluster is situated between amino acids 190 and 239 from the N terminus. Such clusters are also found with other mammalian and avian coronaviruses (Boursnell et al., 1985; Kapke & Brian, 1986; Lapps et al., 1987; Kamahora et aL, 1989) and possibly represent phosphorylation 'hot spots'.
The TCV N protein amino acid sequence shares extensive identity with the analogous sequences of BCV (>/ 99% ; Lapps et al., 1987) and HCV-OC43 (98%; Kamahora et al., 1989) , although it is classified in a separate antigenic group. On the other hand, little similarity was found with the corresponding sequences of IBV (approx. 30%; Boursnell et al., 1985) and TGEV (approx. 30%; Kapke & Brian 1986 ). Furthermore, comparison of the N protein amino acid sequences of TCV with MHV, TGEV and HCV-OC43 reveals regions of up to 69 amino acids with significant sequence identity (>t 90%) which may represent functional domains having survived evolutionary pressures. We showed previously that BCV probes specific to different regions throughout the genome were individually capable of detecting TCV isolates or TCV in clinical specimens (unpublished results). Since homology between BCV and HCV-OC43 has been confirmed by serological studies (Hogue et al., 1984) , and RNA fingerprinting data suggest a close resemblance between the remaining as yet unsequenced portions of the genomes (Lapps & Brian, 1985) , we also expect an overall genomic relationship between TCV and HCV-OC43, although this has to be further investigated.
Only two nucleotide differences were found between the N protein sequences of TCV and BCV. The first is located towards the N terminus of the protein and results in an amino acid change from Ser in TCV to Phe in BCV at amino acid position 15 of the protein, when compared to the BCV sequence published by Lapps et al. (1987 ). However, Cruci6re et al. (1988 reported a serine residue in the same position in another BCV strain, and this is also the case in HCV-OC43 . The second nucleotide difference at amino acid position 53 of the protein is a Gin in TCV and a Leu in BCV, which again is different in HCV-OC43 and MHV strains JHM and A59.
An IORF of 624 nucleotides within the N gene is analogous to one in BCV; the corresponding region of HCV-OC43 contains two IORFs. The presence of IORFs, either inside the N gene or partially in the 3' non-coding region, which are often preceded by an AUG codon in a favourable context for translation initiation (Kozak, 1983) , is frequently observed with other coronaviruses [i.e. BCV (Lapps et al., 1987) , TGEV (Kapke & Brian, 1986) , feline coronavirus (de Groot et al., 1988) , IBV (BoursneU et al., 1985) , HCV-OC43 and HCV strain 229E (Schreiber et al., 1989) ]. It is not yet known whether these IORFs are functional, but it is of interest to determine their possible translation products in virus-infected cells and to verify their translation by means of expression vectors.
Close similarity was also observed between the TCV M protein amino acid sequence and the corresponding sequences of BCV (up to 100K, with a single amino acid difference at position 50) and MHV (86%). The expected membrane topology of the M protein would therefore be likely to resemble the model proposed by Rottier and collaborators (Armstrong et al., 1984; Rottier et al., 1986) . Most of the basic amino acids are situated in the C-terminal half of the protein and might, therefore, interact with the negatively charged RNA and the acidic residues of the N protein as suggested by Sturman et al. (1980) . The N and M protein and intergenic sequences of TCV-Minnesota were up to 100% the same as the sequence of BCV. Therefore, we envisaged that (i) we might have worked with a laboratory-created recombinant virus, (ii) the HRT-18 cells, which are of human origin and used for the production of all our BCV and TCV isolates, might conceal a latent infection with a closely related human coronavirus that could have been activated upon infection with another coronavirus and (iii) the inoculum may have been contaminated with BCV. The second possibility was not likely as hybridization assays with BCV-specific probes on supernatants or nucleic acid from mock-infected HRT-18 cells (Verbeek & Tijssen, 1988) , did not reveal any indication of this and neither did amplification by PCR using nucleic acid from mock-infected cells (Fig. 4) . In order to rule out all three possibilities, RNA from different TCV-positive clinical specimens was isolated for cDNA synthesis and amplification by PCR of fragments corresponding to the N terminus or the complete translational reading frame of the M protein (Fig. 4 ). The addition of tRNA to the samples, as a co-precipitator and a competitor for RNases was essential for the isolation of RNA templates suitable for PCR.
Sequence analysis of the cloned fragments from clinical samples showed that the single amino acid difference between the TCV and BCV M sequences at position 50 of the protein was found again in the Nterminal translated sequence of the amplified 223 bp fragment from clinical isolate number 5 (Fig. 5) . This difference was not observed in the corresponding fragments of any other isolate (Fig. 5) . Complete identity was also found between the TCV M protein sequence, which was amplified from clinical specimen 6 (Fig. 4) , and the sequence of BCV (Fig. 5) . The data obtained from these experiments are fully consistent with the M nucleotide sequence obtained for the TCV strain Minnesota.
The only remaining ambiguity is the type of glycosyla-tion of the M protein which is N-and O-linked in TCV and BCV (Lapps et al., 1987) , respectively, although the nucleotide sequence of this region is the same in both viruses. In addition to the possible O-glycosylation sites there is one potential site for N-glycosylation (Asn-Phe-Ser) within the first 28 Nterminal residues of the TCV M protein and which is, by maximum alignment of the amino acid sequences of HCV-OC43, TGEV, MHV, BCV and IBV, found at the same position in MHV, BCV and TGEV, but not in IBV (Fig. 6) . The latter two viruses, in which the M proteins have N-linked oligosaccharide side-chains, possess an additional one (TGEV) or two (IBV) potential Nglycosylation sites further upstream, while HCV-229E has one potential N-terminal glycosylation site at another position (Fig. 6 ). Whether the single Nglycosylation site is glycosylated in TCV remains to be seen. The data presented here show that TCV is extremely closely related to BCV to the point that they cannot be distinguished on the basis of the nucleotide sequences so far known. There is expected to be an overall genomic homology as BCV probes to different genomic locations are efficient in detecting TCV isolates (unpublished results). We have also succeeded in amplifying the complete TCV S gene (data not shown), using primer combinations selected from a recently published BCV S gene sequence (Boireau et al., 1990) . It is expected that these genes may contain more differences because monoclonal antibodies against the S protein enabled differentiation of the two viruses .
Interestingly, although TCV, BCV and HCV-OC43 must have only recently diverged from each other, they possess different target cell specificities in vitro and infect different animal species. HCV-OC43 causes mainly respiratory diseases, whereas BCV and TCV affect the gastrointestinal system. However, the pathogenicity of TCV and BCV isolates for turkey poults (unpublished results), as well as their c.p.e, in vitro are different . Sequence analysis of the S protein responsible for cell attachment should reveal differences concerning regions important for host cell specificity. The predicted amino acid sequence homology between TCV and BCV, thus far analysed, supports our proposal for the reclassification of TCV, which was previously based mainly on their antigenetic relatedness .
